AbCellera's success is unprecedented: what have we learned?

David Sinton; Shana O. Kelley

doi:10.1039/d1lc00155h

AbCellera's success is unprecedented: what have we learned?

David Sinton, Shana O. Kelley^*

^*Corresponding author for this work

Chemistry

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

The search for antibody therapeutic candidates is a timely and important challenge well-suited to lab on a chip approaches. Vancouver-based AbCellera Biologics Inc. developed a microfluidic antibody screening platform, ancillary technologies, and a service-based drug discovery business model that has proved a tremendous success. We take the opportunity here to reflect on what enabled this success. We consider the common lab on a chip motivations that were part of their success, and those that were not.

Original language	English (US)
Pages (from-to)	2330-2332
Number of pages	3
Journal	Lab on a Chip
Volume	21
Issue number	12
DOIs	https://doi.org/10.1039/d1lc00155h
State	Published - Jun 21 2021

Funding

Governments are often criticized as having a poor record in picking winners. However $175m CAD from the Canadian government into AbCellera in May 2020 was a wise investment and an accelerant. The technology also benefited from early funding from the Canadian Institute for Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC) and other sources. While we don't know the details of grant funding that supported the development of the AbCellera, the return on these investments is substantial given the billions of dollars of value and wealth creation.

ASJC Scopus subject areas

Bioengineering
Biochemistry
General Chemistry
Biomedical Engineering

Access to Document

10.1039/d1lc00155h

Cite this

@article{e8f456581c2a4dae9753fee875b44ef7,

title = "AbCellera's success is unprecedented: what have we learned?",

abstract = "The search for antibody therapeutic candidates is a timely and important challenge well-suited to lab on a chip approaches. Vancouver-based AbCellera Biologics Inc. developed a microfluidic antibody screening platform, ancillary technologies, and a service-based drug discovery business model that has proved a tremendous success. We take the opportunity here to reflect on what enabled this success. We consider the common lab on a chip motivations that were part of their success, and those that were not.",

author = "David Sinton and Kelley, {Shana O.}",

note = "Funding Information: Governments are often criticized as having a poor record in picking winners. However $175m CAD from the Canadian government into AbCellera in May 2020 was a wise investment and an accelerant. The technology also benefited from early funding from the Canadian Institute for Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC) and other sources. While we don't know the details of grant funding that supported the development of the AbCellera, the return on these investments is substantial given the billions of dollars of value and wealth creation. Publisher Copyright: {\textcopyright} The Royal Society of Chemistry 2021.",

year = "2021",

month = jun,

day = "21",

doi = "10.1039/d1lc00155h",

language = "English (US)",

volume = "21",

pages = "2330--2332",

journal = "Lab on a Chip",

issn = "1473-0197",

publisher = "Royal Society of Chemistry",

number = "12",

}

TY - JOUR

T1 - AbCellera's success is unprecedented

T2 - what have we learned?

AU - Sinton, David

AU - Kelley, Shana O.

N1 - Funding Information: Governments are often criticized as having a poor record in picking winners. However $175m CAD from the Canadian government into AbCellera in May 2020 was a wise investment and an accelerant. The technology also benefited from early funding from the Canadian Institute for Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC) and other sources. While we don't know the details of grant funding that supported the development of the AbCellera, the return on these investments is substantial given the billions of dollars of value and wealth creation. Publisher Copyright: © The Royal Society of Chemistry 2021.

PY - 2021/6/21

Y1 - 2021/6/21

N2 - The search for antibody therapeutic candidates is a timely and important challenge well-suited to lab on a chip approaches. Vancouver-based AbCellera Biologics Inc. developed a microfluidic antibody screening platform, ancillary technologies, and a service-based drug discovery business model that has proved a tremendous success. We take the opportunity here to reflect on what enabled this success. We consider the common lab on a chip motivations that were part of their success, and those that were not.

AB - The search for antibody therapeutic candidates is a timely and important challenge well-suited to lab on a chip approaches. Vancouver-based AbCellera Biologics Inc. developed a microfluidic antibody screening platform, ancillary technologies, and a service-based drug discovery business model that has proved a tremendous success. We take the opportunity here to reflect on what enabled this success. We consider the common lab on a chip motivations that were part of their success, and those that were not.

UR - http://www.scopus.com/inward/record.url?scp=85107967516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107967516&partnerID=8YFLogxK

U2 - 10.1039/d1lc00155h

DO - 10.1039/d1lc00155h

M3 - Review article

C2 - 34095928

AN - SCOPUS:85107967516

SN - 1473-0197

VL - 21

SP - 2330

EP - 2332

JO - Lab on a Chip

JF - Lab on a Chip

IS - 12

ER -

AbCellera's success is unprecedented: what have we learned?

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this